Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Dec 19, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how managing blood pressure during lung cancer surgery and using a medication called dexamethasone can affect patients' recovery and long-term health after surgery. Lung cancer surgery is important for treating non-small cell lung cancer, but many patients experience complications afterward. The researchers want to find out if better control of blood pressure and the use of dexamethasone can lead to improved outcomes for patients.

To participate in this study, you need to be between 50 and 90 years old, have a specific type of lung cancer that can be surgically removed, and be scheduled for surgery that will last more than two hours. Unfortunately, if you have other serious health issues, such as uncontrolled high blood pressure or other types of cancer, you may not be eligible to join. If you decide to participate, you will be asked to sign a consent form, and throughout the study, you will receive close monitoring and care to help ensure your safety and well-being during and after your surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged \>50 years but \<90 years.
• • Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \>2 hours.
• • Agree to participate in this study and sign the informed consent.
• Exclusion Criteria:
• • Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.
• • Recurrent or metastatic lung cancer.
• • History of cancer or complicated with cancer in other organs.
• • Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.
• • Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg); or requirement of vasopressors to maintain blood pressure.
• • Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.
• • Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).
• • Any other circumstances considered unsuitable for study participation by attending physicians or investigators.